Kura Oncology Reports Q3 2026 Results with Strong KOMZIFTI Revenue Growth
Kura Oncology reported significant commercial momentum in its third quarter of 2026, driven by the rapid adoption of KOMZIFTI. Net product revenue reached $13.9 million, marking a 53% sequential increase from Q2 2026. This growth was supported by a 30% rise in new patient starts and a 40% expansion in prescribing accounts as field teams successfully penetrated high-priority leukemia accounts. Despite a net loss of $70.2 million, the company demonstrated improved fiscal discipline with decreases in both R&D and SG&A expenses compared to the previous year. Kura maintains a strong liquidity position with $492.1 million in cash and equivalents, which management expects will fund operations through 2028 trial results. Future revenue is bolstered by anticipated milestone payments from Kyowa Kirin totaling approximately $180 million.
Topics: cash runway financing net loss product adoption revenue growth
Read the full article at Motley Fool
Part of the story Kura Oncology Reports Q3 2026 Results with Strong KOMZIFTI Revenue Growth (13 articles)